Search

News Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency –⁠ Real-World Data

Even in patients with secondary immunodeficiency (SID), immunoglobulin substitution can be indicated. Intravenous (IVIG) therapy is considered effective based on studies, but subcutaneous (SCIG) therapy is only based on experiences with patients having primary immunodeficiency (PID). The Italian study presented below, therefore, investigated the efficacy and safety of SCIG in patients with SID.

Source: Primary and Secondary Immunodeficiencies 2. 10. 2023

News Incidence of Osteoporosis in Patients with Atrial Fibrillation Treated with Different Oral Anticoagulants

Previous research has suggested an increased risk of osteoporosis and osteoporotic fractures in patients with atrial fibrillation treated with warfarin. A recent analysis also identified a higher incidence of osteoporosis in patients treated with warfarin or direct oral anticoagulants (DOACs). However, less is known about the risk of this disease when using DOACs compared to warfarin. Therefore, Australian doctors compared its incidence in patients treated with different oral anticoagulants for atrial fibrillation (AF) in a population cohort study using data from a nationwide primary care database.

Source: Anticoagulant Treatment 16. 10. 2023

News Results of Levothyroxine Treatment in Pregnant Women with Recurrent Pregnancy Losses with Subclinical Hypothyroidism or Anti-TPO Antibody Positivity

A recent meta-analysis of 15 studies involving a total of 1911 women with a history of recurrent pregnancy losses and positivity for thyroid peroxidase antibodies (TPOAb) or subclinical hypothyroidism showed the benefits of administering levothyroxine on pregnancy outcomes. Women with TPOAb experienced reductions in preterm births, miscarriages, premature rupture of membranes, and fetal growth retardation. Women with subclinical hypothyroidism saw an increase in live births and a decrease in miscarriages.

Source: Thyroid Disorders 16. 10. 2023

News ERS 2023: Erdostein and its Metabolite Met-1 Modulate Innate Immunity and Oxidative Stress in SARS-CoV-2 Infection

As part of the September congress of the European Respiratory Society (ERS 2023), the issue of COVID-19 was also addressed. Among the late-breaking messages was an e-poster by experts from the University of Milan, who in their study examined the potential of erdosteine and its active metabolite Met-1 in treating this disease, based on research into its application to cells infected with SARS-CoV-2.

Source: Cough Therapy 18. 10. 2023

News Benefit of Empagliflozin in Patients with Chronic Kidney Disease –⁠ Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type 2 diabetes mellitus (T2DM) and chronic heart failure regardless of ejection fraction value. Its impact on renal function and the prognosis of patients with chronic kidney disease (CKD) irrespective of the presence of T2DM was specifically evaluated in the double-blind placebo-controlled EMPA-KIDNEY study.

Source: Diabetes 18. 10. 2023

News The Latest Updates of ESC Recommendations for Heart Failure Treatment

What is new in heart failure therapy? At the annual congress of the European Society of Cardiology (ESC), held from August 25–28, 2023 in Amsterdam, updates to clinical guidelines were traditionally presented. One of these was an update to the 2021 recommendations concerning the diagnosis and treatment of acute and chronic heart failure (HF). Below you will find a brief summary of the key changes.

Source: Heart Failure 18. 10. 2023

News How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?

In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in secondary prevention according to recommended procedures. However, the question could be their long-term effect on clinical outcomes, as different results can be found in the literature –⁠ this fact led the authors of the work cited below to perform a systematic review and meta-analysis of studies dedicated to this issue.

Source: Cardiovascular Continuum 25. 10. 2023

News Thanks to Buccolam, the reality of suppressing convulsive seizures in children and adolescents approaches parents' ideal management

What crosses the mind of a parent when they notice their epileptic child or adolescent is having a convulsive seizure? They want it to be over quickly and safely. What constitutes the integral part that makes this wish a reality? And how does the newest treatment modality, buccally administered midazolam (Buccolam), address these needs?

Source: Quick aid for acute convulsive seizures in children and adolescents 25. 10. 2023

News Multimodal Treatment of Prostate Cancer in a Patient with Exceptionally Long Overall Survival −⁠ Case Report

A recently published case study by Romanian authors presents a rare instance of long-term survival (15 years) in a patient with locoregional prostate cancer that later metastasized. The case illustrates the possibilities offered by currently available modern treatment modalities.

Source: Oncological Treatment 26. 10. 2023

News Benefit of Short-term Androgen-deprivation Therapy Added to Radiotherapy of Localized Prostate Cancer for Long-term Survival

Androgen-deprivation therapy is associated with several adverse effects that also affect quality of life or increase the risks of serious age-related health problems. An extensive study focused on the benefits of short-term administration of androgen-deprivation therapy as an adjunct to radiotherapy in patients with prostate cancer and monitored its long-term impact on survival and the rate of late treatment toxicity.

Source: Oncological Treatment 26. 10. 2023

News Effect of Extended-Release Metformin on Cognitive Functions in Older Frail Women with Diabetes and Hypertension

Women have a higher risk of geriatric frailty regardless of age and menopausal status. This risk further increases with the presence of diabetes and hypertension, which also elevate the risk of cognitive dysfunction. According to available data, metformin may reduce the risk of developing frailty in postmenopausal women. A recently published Italian study, LEOPARDESS, aimed to evaluate the effect of extended-release metformin on the cognitive functions of this population of women.

Source: Cardiovascular Risks 14. 3. 2024

News Safe Long-term Treatment of Nasal Symptoms in Patients with Perennial Allergic Rhinitis

In persistent allergic rhinitis, achieving symptom control is often difficult despite pharmacological treatment and minimizing contact with the allergen. Good efficacy in clinical studies has been shown with combined therapy of intranasal antihistamines with locally acting corticosteroids. The presented study evaluated the long-term safety profile and efficacy of a fixed combination of olopatadine with mometasone.

Source: Life Without Allergic Rhinitis 24. 3. 2022

News Effect of Combination Therapy on Symptoms of Allergic Rhinitis

The aim of the study presented below by authors from the USA was to evaluate the efficacy, safety, and tolerability of treatment with the nasal spray GSP301 containing a fixed combination of active ingredients, compared to placebo and monotherapies during a 14-day therapy in adult and adolescent patients with allergic rhinitis.

Source: Life Without Allergic Rhinitis 24. 3. 2022

News Does the choice of therapy for primary hypertension in patients with COVID-19 affect the severity of the disease?

The effect of two commonly used antihypertensives was evaluated in a randomized clinical trial in patients with primary hypertension and COVID-19.

Source: Sartans in the Treatment of Hypertension 24. 3. 2022

News Prim. Pavel Jindra: Biosimilars are an accessible and effective treatment modality in hematooncology

“Based on our experience so far, biosimilars represent an effective and safe alternative to original molecules. We are not afraid to use them anywhere in approved indications, and we are not afraid of switching either. Biosimilars are a significant step towards greater accessibility of hematooncological treatment for a wide group of patients,” states the head of the Hematology-Oncology Department of FN Plzeň, MUDr. Pavel Jindra, Ph.D., in our current interview.

Source: Oncological Treatment 24. 3. 2022